Suppr超能文献

非酒精性脂肪性肝病、胰岛素抵抗与代谢综合征之间病理生理联系的综合综述

A Comprehensive Review of Pathophysiological Link Between Non-alcoholic Fatty Liver Disease, Insulin Resistance, and Metabolic Syndrome.

作者信息

Januario Eudith, Barakat Aly, Rajsundar Abhivanditha, Fatima Zahra, Nanda Palienkar Varda, Bullapur Arjun V, Singh Brar Sunchandandeep, Kharel Punam, Koyappathodi Machingal Mishal Mohammed, Backosh Amena

机构信息

Medicine, American University of Antigua, Osbourn, ATG.

Internal Medicine, Medway NHS Foundation Trust, Gillingham, GBR.

出版信息

Cureus. 2024 Dec 13;16(12):e75677. doi: 10.7759/cureus.75677. eCollection 2024 Dec.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic condition characterized by hepatic steatosis in the absence of significant alcohol consumption and is increasingly recognized as the hepatic manifestation of metabolic syndrome (MetS). This review aims to explore the molecular mechanisms underlying the interaction between NAFLD, insulin resistance (IR), and MetS, with a focus on identifying therapeutic targets. A comprehensive review of existing literature on NAFLD, IR, and MetS was conducted. The review indicates that IR contributes to hepatic lipid accumulation through increased lipolysis, elevated free fatty acid flux, and impaired fatty acid oxidation, while MetS exacerbates the condition by promoting visceral adiposity, chronic inflammation, and impaired lipid metabolism. Additionally, dysbiosis and increased intestinal permeability in the gut-liver axis worsen IR, leading to a vicious cycle of metabolic dysfunction. In conclusion, addressing these interconnected pathways could enhance therapeutic strategies and reduce the burden of NAFLD-related complications.

摘要

非酒精性脂肪性肝病(NAFLD)是一种慢性疾病,其特征为在无大量饮酒情况下出现肝脏脂肪变性,并且越来越被认为是代谢综合征(MetS)的肝脏表现。本综述旨在探讨NAFLD、胰岛素抵抗(IR)和MetS之间相互作用的分子机制,重点是确定治疗靶点。对关于NAFLD、IR和MetS的现有文献进行了全面综述。该综述表明,IR通过增加脂肪分解、提高游离脂肪酸通量和损害脂肪酸氧化导致肝脏脂质蓄积,而MetS则通过促进内脏肥胖、慢性炎症和脂质代谢受损使病情加重。此外,肠道-肝脏轴中的微生物群失调和肠道通透性增加会使IR恶化,导致代谢功能障碍的恶性循环。总之,解决这些相互关联的途径可以加强治疗策略并减轻NAFLD相关并发症的负担。

相似文献

2
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:55-65. doi: 10.1016/j.mce.2015.02.018. Epub 2015 Feb 24.
3
4
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
J Hepatol. 2019 Nov;71(5):1012-1021. doi: 10.1016/j.jhep.2019.06.031. Epub 2019 Jul 10.
6
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment.
Diabetes Obes Metab. 2022 Feb;24 Suppl 2:15-27. doi: 10.1111/dom.14651. Epub 2022 Jan 24.
7
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477. eCollection 2022 May.
9
Comparison of Non-invasive Liver Fat Scoring Systems as Markers of Metabolic Dysfunction-Associated Liver Disease.
Cureus. 2024 Oct 23;16(10):e72222. doi: 10.7759/cureus.72222. eCollection 2024 Oct.
10
Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload.
Mol Metab. 2021 Sep;51:101235. doi: 10.1016/j.molmet.2021.101235. Epub 2021 Apr 16.

引用本文的文献

本文引用的文献

3
Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort.
J Cachexia Sarcopenia Muscle. 2023 Feb;14(1):260-269. doi: 10.1002/jcsm.13125. Epub 2022 Nov 20.
4
Insulin Resistance: From Mechanisms to Therapeutic Strategies.
Diabetes Metab J. 2022 Jan;46(1):15-37. doi: 10.4093/dmj.2021.0280. Epub 2021 Dec 30.
5
Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD.
Int J Mol Sci. 2021 Nov 2;22(21):11905. doi: 10.3390/ijms222111905.
7
A PERKy way to make mitochondrial cristae.
Trends Endocrinol Metab. 2021 Jul;32(7):417-419. doi: 10.1016/j.tem.2021.04.003. Epub 2021 May 3.
8
Role of Insulin Resistance in MAFLD.
Int J Mol Sci. 2021 Apr 16;22(8):4156. doi: 10.3390/ijms22084156.
9
NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2.
Can J Gastroenterol Hepatol. 2021 Feb 17;2021:6613827. doi: 10.1155/2021/6613827. eCollection 2021.
10
Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).
Transl Gastroenterol Hepatol. 2021 Jan 5;6:2. doi: 10.21037/tgh.2019.09.06. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验